The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: Proposal based on interval look during upfront surgery setting treatment

Japanese Journal of Clinical Oncology

Volumn 40, Issue 1, 2009, Pages 36-41

  Onda, Takashi ^a,b   Yoshikawa, Hiroyuki ^a,c   Yasugi, Toshiharu ^a,d   Matsumoto, Koji ^a,c   Taketani, Yuji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Chemo gynecology; Gynecol surg; Neoadjuvant therapy; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; LONG TERM CARE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; SALPINGOOOPHORECTOMY; SURVIVAL RATE; ADJUVANT THERAPY; FOLLOW UP; JAPAN; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM; OVARY TUMOR; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 74949109379     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp127     Document Type: Article

References (19)

1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
2. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006;107:77-85.
3. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103:559-64.
4. Winter WE, III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621-7.
5. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000;78(3 Pt 1):269-74.
6. Dauplat J, Le Bouedec G, Pomel C, Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. SeminSurgOncol2000;19: 42-8.
7. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146-50.
8. Onnis A, Marchetti M, Padovan P, Castellan L. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynaecol Oncol 1996;17:393-6.
9. Kayikçioǧlu F, Kose MF, Boran N, Caliskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001;11:466-70.
10. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001;92:2585-91.
11. Onda T, Kamura T, Ishizuka N, Katsumata N, Fukuda H, Yoshikawa H. Feasibility study of neoadjuvant chemotherapy followed by interval cytoreductive surgery for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Jpn J Clin Oncol 2004;34:43-5.
12. Onda T, Kobayashi H, Nakanishi T, Hatae M, Iwasaka T, Konishi I, et al. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol Oncol 2009;113:57-62.
13. Vergote IB, De Wever I, Decloedt J, Tjalma W, Van Gramberen M, van Dam P. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 2000;27(3 Suppl 7):31-6.
14. Onda T, Matsumoto K, Shibata T, Sato A, Fukuda H, Konishi I, et al. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn J Clin Oncol 2008;38:74-7.
15. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.
16. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:2489-97.
17. Le T, Alshaikh G, Hopkins L, Faught W, Fung MF. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Ann Surg Oncol 2006;13:1711-6.
18. Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992;45:284-9.
19. Bertelsen K, Jakobsen A, Stroyer J, Nielsen K, Sandberg E, Andersen JE, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 1993;49:30-6.